The Novel Nutraceutical KJS018A Prevents Hepatocarcinogenesis Promoted by Inflammation

Figure 1

KJS018A induces apoptosis in hepatic malignant cells. (a) Apoptosis assay of SNU398 and HepG2 after being treated with different concentrations of KJS018A (0, 50, 100, and 150 μg/mL). (b) Percentage of apoptotic cells after KJS018A treatment (0, 50, 100, and 150 μg/mL). (c) IC₅₀ at 24 h for SNU398 and HepG2 under KJS018A treatment. (d) Western blotting of SNU398 and HepG2 lysates after 24 h exposed with different concentrations of KJS018A (0, 50, 100, and 150 μg/mL). P< 0.001; P< 0.0001. The experiment was repeated 3 times.

(a)

(b)

(c)

(d)